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DockingDietary ﬂavonoids are important contributors to cancer prevention, due to their interactions with CYP family
enzymes. This study describes the application of in silico tools to study the metabolism of dietary ﬂavonoid
compounds such as quercetin, rutin, naringenin and naringin, aiming to propose their potential metabolites
and chemical structures and also to investigate the abilities of these compounds to interact with cytochrome
P450 CYP1A2 and CYP2C9 isoforms. The reactions founded suggest that the presence of the sugar chain may
account for signiﬁcant change in the position of the ﬂavonoid in the active site, due to the steric contacts. An-
other important ﬁnding is the participation of the amino acid residues in the metabolism. In CYP2C9, the
Asn474, Ser209, Thr304 and Arg108 residues participated almost in all of the metabolically active conforma-
tions, suggesting that these residues are important for the regioselectivity and positioning of the substrate.
The same was observed for the Asp313, Phe226, Phe256 and Phe260 residues of the CYP1A2 isoform. The re-
sults presented here afford new opportunities for improving the application of dietary ﬂavonoids for the pre-
vention of chronic disorders, as they're capable to be readily metabolized by CYP450 family.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Flavonoids are a large group of naturally occurring polyphenolic
compounds that constitute the most abundant class of dietary natural
products and are present in fruits, vegetables, beverages and various
dietary supplements. Extensive investigations of their bioactivity in the
past 30 years have demonstrated their potential to prevent various dis-
eases, including cardiovascular disease, inﬂammatory disorders, viral
infections, diabetes and neurological conditions (Andres, Donovan, &
Kuhlenschmidt, 2009; Rathee et al., 2009; Scalbert & Williamson,
2000; Vauzour, Vafeiadou, Rodriguez-Mateos, Rendeiro, & Spencer,
2008). Among the wide range of biochemical and pharmacological
properties, one of their most investigated activities is their cancer pre-
vention. Dietaryﬂavonoids can inhibit tumor formation and theprolifer-
ation of cancer cells through various biological mechanisms. Recent data
suggests that in addition to the inhibition of procarcinogen activation,
ﬂavonoids exert chemotherapeutic roles by undergoing cytochrome
P450mediated oxidativemetabolism to conversion products that inhib-
it tumor cell growth (Androutsopoulos, Mahale, Arroo, & Potter, 2009;
Androutsopoulos, Papakyriakou, Vourloumis, Tsatsakis, & Spandidos,
2010; Arroo et al., 2009). Consequently, ﬂavonoids are considered to
be the key natural products that provide themost essential link between
diet and the prevention of chronic disorders (Lampila, van Lieshout,metabolism.
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 OA license.Gremmen, & Lähteenmäki, 2009). Therefore, it would be useful to
know the biological fate of these compounds. Notably, ﬂavonols such
as quercetin and rutin and ﬂavanones as naringenin and naringin
(Fig. 1) are abundant in foods that are consumed daily worldwide.
Cytochrome P450 (CYPs) are heme-containing monooxygenases
that play an important role in the biosynthesis and metabolism of
many endogenous compounds, such as hormones, sterols and vitamins.
CYPs also play a role in the metabolism and detoxiﬁcation of a large
number of xenobiotics, such as drugs, carcinogens and pollutants
(Nebert & Dieter, 2000). The most important CYP450 isoforms are the
CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4, which account for the oxidative
metabolism of >90% of the drugs on themarket (deMontellano, 2010).
The isoforms CYP1A2 and CYP2C9 are the major enzymes responsible
for the phase I metabolism of ﬂavonoids (Miners & Birkett, 1998).
Experimental investigation of the metabolism of small molecules is
still highly resource-demanding and challenging (Tarcsay & Keseru,
2011); which is why in recent years substantial efforts have been
applied to develop computational approaches to predict thesemetabol-
ic outcomes (Kirchmair et al., 2012). Site of metabolism (SOM) predic-
tionmodels serve as tools to helpmedicinal chemists decidewhich sites
on a molecule to modify to avoid undesired metabolism. These modiﬁ-
cations may help in optimizing drug half-life and reducing drug–drug
interactions, and therefore, they may aid in designing new compounds
with improved pharmacokinetics (Braga et al., 2012; Czodrowski,
Kriegl, Scheuerer, & Fox, 2009). The in silico metabolism models can
be classiﬁed mainly into two categories: (i) ligand-based, which uses
the reactivity of the substrate; and (ii) structure-based or docking-based,
which uses the binding of the substrate to a CYP450 enzyme
(Stjernschantz, Vermeulen, & Oostenbrink, 2008).
Fig. 1. Chemical structures of quercetin, rutin, naringenin and naringin. Glc=glycoside.
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compounds such as quercetin, rutin, naringenin and naringin using
ligand- and structure-based approaches to propose their potential
metabolites and chemical structures and also to investigate the abili-
ties of these compounds to interact with cytochrome P450 CYP1A2
and CYP2C9 isoforms.
2. Material and methods
2.1. MetaPrint2D prediction
MetaPrint2D is an improved algorithm for the prediction of the site of
metabolism that predicts xenobiotic metabolism through data-mining
and statistical analysis of the knownmetabolic transformations reported
in scientiﬁc literature (Carlsson, Spjuth, Adams, Glen, & Boyer, 2010). The
method uses a database of atom environments found in molecules
known to undergo metabolic transformation. The Symyx(R) (previously
MDL) Metabolite database, available at http://www.symyx.com/, is an
example of such a database. The software was used on the web platform
(http://www-metaprint2d.ch.cam.ac.uk/) by uploading the SMILES
string of each ﬂavonoid studied. We used the two available versions,
MetaPrint2D and MetaPrint2D-React. MetaPrint2D predicts sites of
phase I metabolism, which is deﬁned as the addition of oxygen, as in
hydroxylation, oxidation and epoxidation or elimination reactions.
MetaPrint2D-React can make predictions concerning a wider range of
reactions of phases I and II; it is able to predict the types of transforma-
tions that can easily take place at the site of metabolism and the likely
metabolite formed. The ﬁngerprint matching was set to strict, with the
following values of parameters: number of exact levels: 4; similarity
threshold: 0.1; ﬁrst weight: 1.0; second weight: 1.0; third weight: 1.0;
fourth weight: 1.0; ﬁfth weight: 0.5; and sixth weight: 0.25.
2.2. Docking studies
The crystal structures of the ﬂavonoids quercetin (PDB ID: 3NVY),
rutin (PDB ID: 1RY8) and naringenin (PDB ID: 2UXU) that were
obtained from the Protein Data Bank (PDB) were isolated and mini-
mized using the MMFF94x force ﬁeld available at Molecular Operating
Environment (MOE) software, version 2008.10 (Chemical Computing
Group Inc., Montreal, Canada) for docking studies. The naringin struc-
ture was built using naringenin (ﬂavone moiety) and rutin (sugar moi-
ety) as templates using the MOE software and minimized in the same
way as the other ﬂavonoids.
The crystal structure of human cytochrome P450 CYP1A2 and
CYP2C9 with highest resolution was obtained from the PDB. The acces-
sion code for CYP1A2 in complex with α-naphthoﬂavone with 1.95 Å
resolution is 2HI4 (Sansen et al., 2007) and the accession code for
CYP2C9 co-crystallized with ﬂurbiprofen with 2.00 Å resolution is
1R9O (Wester et al., 2004).
For docking studies, the CYP2C9 and CYP1A2 structures were pre-
pared by ﬁrst removing the ligand molecule from the enzyme active
site and then by removing the water molecules with the exception
of the active site water molecules (wat600, wat819 and wat842 forCYP2C9 (Wester et al., 2004), and wat733 for CYP1A2 (Sansen et al.,
2007). Then, the AutoDockTools 4.0 version 1.5.2 was used to add hy-
drogen atoms to the enzyme 3D structures. Partial atomic charges
were then assigned to the macromolecule as well as ligands.
Gasteiger charges were used for the ligands, and Kollman charges
were used for the protein. The iron metal atom from the heme
group was set to a+3 charge (Oda, Yamaotsu, & Hirono, 2005)
Docking calculations were carried out using AutoDock 4.0 and
AutoGrid 4.0 (Morris et al., 2009). Grids were centered on coordinates
2.968, 25.818, and−0.185, with a 0.375 Å grid spacing and dimensions
of 54 Å×60 Å×50 Å points on x, y, and z coordinates for CYP2C9, and
on coordinates 7.308, 21.575, 25.254, with a 0.375 Å grid spacing and
dimensions of 58 Å×56 Å×70 Å points on x, y, and z coordinates for
CYP1A2. Docking was performed with the AutoDock empirical free
energy function, employing the Lamarckian genetic algorithm with
local search (Huey,Morris, Olson, & Goodsell, 2007). One hundred solu-
tions were generated for each docking run with 2500000 energy eval-
uations for each runwere performed for eachmolecule. Cluster analysis
(RMS tolerance of 2.0 Å) was then carried out on the docked results.
The solutions that showed the lowest energy in each individual cluster
were chosen for further analysis. The resulting P450-substrate com-
plexes were reﬁned using the energy minimization procedure.
2.2.1. Docking reﬁnement and energy minimization
The best CYP-substrate complexes selected from the docking were
submitted for energy minimization using Desmond software (Bowers
et al., 2006) with the OPLS-AA force ﬁeld (Jorgensen, Maxwell, &
Tirado-Rives, 1996) via the steepest descent/L-BFGS until the gradient
threshold of 0.05 Kcal/mol/Å was reached.
To determine the possible metabolic sites of substrate, or the met-
abolically active orientations, the distances between the substrate site
and the iron atom of the heme of CYP2C9 or CYP1A2 were measured
and the docking solutions that showed a catalytically active distance
equal or less than 5 Å (H-to-Fe distance) were selected.
3. Results
The atoms of a compound at which metabolic transformations are
centered are termed its ‘sites of metabolism’ (SOM). The SOM for quer-
cetin (1), rutin (2), naringenin (3) and naringin (4) predicted from
MetaPrint2D are shown in Fig. 2. The results are depicted with the
atoms colored according to the likelihood of a metabolic site being
centered on that atom (Carlsson et al., 2010). The SOM for quercetin
(1) predicted by MetaPrint2D (Fig. 2) corresponds to reactions of
phase II metabolism; and therefore, are not the focus of this study.
Although not predicted by MetaPrint2D, the C5′position of quercetin
is a known site of hydroxylation by CYP enzymes (Androutsopoulos et
al., 2010) and therefore, must be considered in the structure-based
metabolism study. MetaPrint2D-React can make predictions concerning
a wider range of reactions, and is able to predict the types of transfor-
mation that can take place at site of metabolism, and the likely me-
tabolite formed. In Fig. 2, MetaPrint2D indicated that the reactions in
the positions 7, 5, 4′ and 3′ for rutin (2); 4, 5, 7 and 4′ for naringenin
(3), 4′ for naringin (4), corresponded to reactions of phase IImetabolism.
The SOM thatwere predicted byMetaPrint2D to bemost likely to be
metabolized (colored in red) for rutin (2) are the O7′ oxygen atom
(O-dealkylation) and the C8′ carbon atom (dealkylation) located in
3-rutinose moiety, followed by the O11′ oxygen atom (O-dealkylation)
and the C12′ carbon atom (dealkylation), which are colored in yellow
(Fig. 2). Because it is a quercetin derivative, another SOM that could
be proposed for rutin is the aromatic hydroxylation reaction of the C5′
atom of B ring.
The SOM that are most likely to be metabolized (colored in yellow)
for naringenin (3) are the C3 carbon of the pyrane ring by hydroxyl-
ation, followed by the C2 carbon bydealkylation/hydroxylation. In addi-




























Fig. 2. Plot of the MetaPrint2D predictions. Site of metabolism: the atoms that most likely will be metabolized or normalized occurrence ratio (NOR) are colored according to the
likelihood of a metabolic site. A high likelihood is shown in red, medium likelihood is shown in orange, low likelihood is shown in green and very low likelihood is not colored. A
high NOR indicates a more frequently reported site of metabolism in the metabolite database for quercetin (1), rutin (2), naringenin (3) and naringin (4).
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metabolism by aromatic hydroxylation reactions (Androutsopoulos,
Papakyriakou, Vourloumis, & Spandidos, 2011; Androutsopoulos et al.,
2010).
For naringin (4), MetaPrint2D predicted phase I reactions at oxygen
O7′, by O-dealkylation, and at carbon C8′ by dealkylation in the
7-rhamnoglucose chain to be the positions that are most likely to be
metabolized (colored in red), followed by the C10′ carbon in the same
chain by dealkylation (colored in yellow), and in the O9′ oxygen by
O-dealkylation. The pyrane ring also contains predicted phase I reac-
tions at carbon C3 (colored in green) by hydroxylation. As for the
other ﬂavonoids, another SOM that is proposed for naringin is metabo-
lism by aromatic hydroxylation of the phenolic ring at carbons C3′ and
C5′ of B ring.
The metabolic reaction of a xenobiotic consists of a series of
processes, including substrate binding to the enzyme, catalytic reac-
tion of a substrate by the enzyme and the release of a metabolite
from the enzyme. Force ﬁeld-based docking techniques can mimic
this process for complex formation and the dynamic motions of the
substrate-enzyme complex (Wang, Lai, & Wang, 2002). Substrate
orientation within the active site of a CYP is a crucial factor for
CYP-mediated metabolism. Therefore, docking studies can be particu-
larly useful for gaining selectivity and steric information about poten-
tial compounds and can be used to predict the sites of metabolism
and possible toxic metabolites of potential compounds (Braga et al.,
2012; Stjernschantz et al., 2008).
To determine the efﬁciency of the docking parameters and the size of
the grid box, the docking protocol was evaluated. Each co-crystallized
ligand was re-docked into the corresponding binding site, and the accu-
racy of each prediction was assessed on the basis of the RMSD between
the coordinates of the heavy atoms of the ligand in the top docking
orientation and those in the crystal structure. The CYP2C9-ﬂurbiprofencomplex (PDB ID: 1R9O) (Wester et al., 2004)was used for the validation
run where ﬂurbiprofen was docked into CYP2C9. Docking using the
AutoDock software with the rigid protein structure accurately predicted
the placement of ﬂurbiprofen in the crystal structure of human CYP2C9
with a RMSD of 1.32 Å. The same validation method was performed for
CYP1A2 co-crystallized with α-naphthoﬂavone (PDB ID: 2HI4) (Sansen
et al., 2007). The placement of α-naphthoﬂavone in the CYP1A2 struc-
ture showed a RMSDof 1.37 Å. The docking protocolwas considered val-
idated because it presented RMSD values between the coordinates of the
heavy atoms of the ligand in the docking orientation and those in the
crystal structure equal or less than 2.0 Å.
Using the validated docking protocol, the four ﬂavonoid com-
pounds were docked into the active site of the CYP2C9 and CYP1A2
enzymes. The docked complexes that predicted metabolically active
states, containing distances from heme iron less than 5 Å, were sub-
mitted for energy minimization, which provides additional structural
relaxation and establishes reasonable model hydrogen bonding pat-
terns. It has been shown that energy minimization of multiple confor-
mations is a highly beneﬁcial post-processing step when docking is
performed (Kroemer, 2007). Moreover, this additional reﬁnement
with an all-atom minimization using a different force ﬁeld can result
in an increase of the docking accuracy.
Visual inspections of the predicted binding modes along with the
scoring values as well as the distance between the substrate site and
the iron atom of the heme of CYP-450 were used to predict the metab-
olism. The visual inspections were aimed at identifying the active site
residues that could potentially position the ﬂavonoid compounds for
the metabolism and/or stabilize transition states. Of the 100 conforma-
tions obtained of each docking run, only some solutions had the sub-
strate positioned at a favorable distance from the heme iron for
metabolism. The docking results are shown in Tables 1 and 2. In these
tables, the distances from the heme iron to themajor site ofmetabolism
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Tables 1 and 2 displays the predictedmetabolites thatwere experimen-
tally conﬁrmed by in vitro ﬁndings.
Tables 1 and 2 show the calculated binding energies of the best-
docked orientations (ΔGcalc), using the Genetic Algorithm (GA)method
scoring function, for CYP2C9 and CYP1A2, respectively. The ΔGcalc dif-
ferences found in the conformations from the docking studies are not
signiﬁcant enough to specify a target for each cytochrome, or for bind-
ing to each ﬂavonoid. According to the docking studies, naringenin
is expected to have two metabolites (M1–M2), whereas naringin is
expected to have four oxidation metabolites (M1–M4). Quercetin is
expected to have only one metabolite (M1) and rutin is expected to
have three metabolites (M1–M3) (Tables 1–2).
Themajor energetically favored binding conformations of naringenin,
naringin, quercetin and rutin in the active site of CYP2C9 and CYP1A2 are
shown in Figs. 3 and 4. Themetabolically active sites after docking studies
presented can be compared in terms of interaction with amino acids and
spatial arrangement.
Fig. 3 shows the docking conformations consistent with the forma-
tion of M1 of naringenin (Fig. 3A and B) and of M2 and M1 of naringin
(Fig. 3C and D, respectively). Analyzing the docked structure of
naringenin with CYP2C9 (Fig. 3A), we can note that the oxygen atoms
in the phenolic ring may be able to form hydrogen bonds with the
Ser209, Asn474 and Thr304 residues, which are recognized as impor-
tant residues in the CYP2C9 active site (D A Smith, Jones, & Walker,
1996). This allows the free phenolic ring to be positioned at a catalytic
distance of 3.25 Å (Table 1, naringenin M1) for C3′aromatic hydroxyl-
ation reaction. When docked in the CYP1A2 structure (Fig. 3B), the
naringenin position changed to allow for a π-stacking interaction with
Phe226 residue, which is located at the top of the CYP1A2 active site.
This suggests that stacking of the rings occurs when the benzene ring
and pyran ring are in close proximity increasing a stable metabolism
of the free phenolic ring with the iron of heme that is presented at
catalytic distance of 3.70 Å for C3′aromatic hydroxylation reaction
(Table 2, naringenin M1).
The docked orientation of naringin with CYP2C9 (Fig. 3C) suggests
that the oxygen atoms of naringin may be able to form hydrogen
bonds with Arg108 and Thr304 residues. These interactions are shown
to position the pyran ring moiety of naringin toward the heme,
supporting the C3 hydroxylation pathway (Table 1, naringin M2).
From the analysis of the docking studies of naringin with CYP1A2
(Fig. 3D), several hydrogen bonds with Asp313, Thr124, Thr498 and
Asp320 residues and with the active site water molecule 733 were
found contributing for the orientation for this pose. According to the
literature, Thr124 is one of the main candidates to form polar contacts
between the CYP1A2 protein and the substrate (Sansen et al., 2007).
This conformation with naringin buried in the active site of CYP1A2
allows the approach of the C3′atom of B ring to the heme iron withinTable 1
Predictions of the site of metabolism from the docking of quercetin, rutin, naringenin and n
CYP2C9
Flavonoid Atom site of metabolism (SOM) d (Å)a SOM reaction typ
Naringenin C3′ or C5′ benzene ring 3.25 Aromatic hydroxy
C3 pyran ring 4.17 Hydroxylation
Naringin C3 pyran ring 2.91 Hydroxylation
O7′ 7-rhamnoglucose chain 3.54 O-dealkylation
O9′ 7-rhamnoglucose chain 2.51 O-dealkylation
Rutin C5′ benzene ring 2.74 Aromatic hydroxy
O7′ 3-rutinose chain 3.98 O-dealkylation
O11′ 3-rutinose chain 3.45 O-dealkylation
Quercetin C5′ benzene ring 4.37 Aromatic hydroxy
a Indicates the distance between the site of metabolism and the heme iron of CYP2C9.
b Calculated free energy of binding using the Genetic Algorithm (GA) method.
c Experimentally conﬁrmed using in vivo or in vitro studies (Breinholt et al., 2002; da Silv
1998).
d Not found for Naringin, but a universal route for ﬂavonoid biotransformation is the C3a catalytic distance of 4.92 Å for hydroxylation reaction (Table 2,
naringin M1). The involvement of the Asp313 residue in both docking
studies with CYP1A2 suggests that this amino acid is very important
in the mechanism for the metabolism of some ﬂavonoids, speciﬁcally
ﬂavanones like naringenin and naringin (Sansen et al., 2007).
Fig. 4 shows the docking conformations consistent with the forma-
tion of M1 of quercetin (Fig. 4A and B) and of M1 and M2 of naringin
(Fig. 4C and D, respectively). The analysis of the docked orientation of
quercetin with CYP2C9 (Fig. 4A) clearly shows important interactions
by hydrogen bonds with the Asn474, Ser209, Thr304 and Ile205
amino acid residues. This conformation allows the phenolic ring to
interact with the catalytic center of the heme at a distance of 4.37 Å
(Table 1, quercetin M1). The proposed reaction for this pose is aromatic
hydroxylation. With CYP1A2 (Fig. 4B), we can see a stacking between
the phenolic ring of quercetin and the Phe226 residue for the aromatic
hydroxylation of the free phenolic ring (Table 2, quercetin M1),
reafﬁrming the indispensable participation of this residue in mecha-
nism for the metabolism of many ﬂavonoids (Sansen et al., 2007).
The best pose for the docked rutin with CYP2C9 (Fig. 4C) is in
favorable position to form several hydrogen bonds with Arg108,
Asn204, Ile205, Val292 and Thr304. These residues may contribute
for the orientation for this position of rutin within the active site of
CYP2C9. Various studies highlighted the key role of Arg108 in the ori-
entation of the substrate (Sykes, McKinnon, & Miners, 2008; Wester
et al., 2004). All these interactions are shown to support the C5′
hydroxylation metabolism of rutin, to form the metabolite M1.
The observed docked pose of rutin with CYP1A2 (Fig. 4D) shows
several hydrogen bonds with the Asn312, Asp313, Thr498 and Asp320
residues.Moreover, rutinwas involved in π–π interactions being placed
between three phenylalanine rings (256 and 260) as observed experi-
mentally forα-naphthoﬂavone (Sansen et al., 2007). These interactions
could help the positioning of the rutin moiety in the active site of
CYP1A2 for metabolism, generating the O-dealkylated metabolite
(Table 2, rutin M2). The distance of the SOM to the iron of the heme is
2.68 Å.
4. Discussion
Metabolism of xenobiotics remains a central challenge for the dis-
covery and development of drugs, cosmetics, nutritional supplements,
and agrochemicals. Experimental investigation of the metabolism of
small organic molecules is particularly resource demanding; hence,
computational methods are of considerable interest to complement
experimental approaches.
It has been postulated that dietary ﬂavonoids exhibit cancer thera-
peutic effects, due to intracellular CYP-mediatedmetabolism to conver-
sion products that inhibit growth of cancerous cells (Androutsopoulos
et al., 2009, 2010). The metabolism of ﬂavonoids in humans as well asaringin with CYP2C9.
e Metabolite ΔGcalcb (kcal/mol) Experimentally observed c
lation M1 −5.98 Yes
M2 −5.83 Yes
M2 −3.82 Yes d
M3 −1.46 No
M4 −1.32 No
lation M1 −2.89 Yes
M2 −1.68 Yes
M3 −2.50 No
lation M1 −6.77 Yes
a et al., 1998; Doostdar et al., 2001; Heim et al., 2002; Hosny et al., 2001; Nielsen et al.,
and C3′-hydroxylation.
Table 2
Predictions of the site of metabolism from the docking of quercetin, rutin, naringenin and naringin with CYP1A2.
CYP1A2
Flavonoid Atom site of metabolism (SOM) d (Å)a SOM reaction type Metabolite ΔGcalcb (kcal/mol) Experimentally observed c
Naringenin C3′ or C5′ benzene ring 3.70 Aromatic hydroxylation M1 −7.61 Yes
Naringin C3′ or C5′ benzene ring 4.92 Aromatic hydroxylation M1 −6.07 Yesd
C3 pyran ring 4.16 Hydroxylation M2 −1.96 Yesd
O7′ 7-rhamnoglucose chain 3.73 O-dealkylation M3 −2.98 No
Rutin C5′ benzene ring 4.87 Aromatic hydroxylation M1 −3.03 Yes
O7′ 3-rutinose chain 2.68 O-dealkylation M2 −4.92 Yes
Quercetin C5′ benzene ring 4.20 Aromatic hydroxylation M1 −7.42 Yes
a Indicates the distance between the site of metabolism and the heme iron of CYP1A2.
b Calculated free energy of binding using the Genetic Algorithm (GA) method.
c Experimentally conﬁrmed using in vivo or in vitro studies (Breinholt et al., 2002; da Silva et al., 1998; Doostdar et al., 2001; Heim et al., 2002; Hosny et al., 2001; Nielsen et al., 1998).
d Not found for Naringin, but a universal route for ﬂavonoid biotransformation is the C3 and C3′-hydroxylation.
106 M.C. Sousa et al. / Food Research International 50 (2013) 102–110in experimental animals, involving enzymes of phase I and II, is complex
and not entirely understood. Therefore, it would be useful to study the
biotransformation of ﬂavonoids using novel methodologies, such as in
silico methods that can bring us closer to understand metabolism and
predict substrate–enzyme interactions.
Flavonoids from ingested fruits or vegetables are expected to be ﬁrst
metabolized in the gut by colonmicroﬂora, where ﬂavonoid glycosides,
such as rutin and naringin are frequently cleaved into free ﬂavonoids
(aglycones), as quercetin and naringenin, and both glycosides and agly-
cones are absorbed (Hodek, Treﬁl, & Stiborová, 2002). The second im-
portant site of ﬂavonoid transformation is the liver, the tissue rich inA B
C D
Fig. 3. The two major energetically favored binding clusters of naringenin and naringin in the
docking studies. (A) C3′ aromatic hydroxylation, (B) C5′ aromatic hydroxylation, (C) C3
CYP1A2 is shown in cartoon (green) with some amino acid residues shown as sticks (the ca
bon atoms are shown in yellow). The heme group is also shown with stick model (the carbphase I and II enzymes. Flavonoids are gradually hydroxylated and/or
O-demethylated by cytochromes P450 and then subjected to conjuga-
tion reactions (glucuronidation, sulfation, O-methylation) catalyzed by
phase II enzymes (Rice-Evans, 2001).
In this study, we used a combination of ligand- and structure-based
metabolism prediction tools to investigate the metabolism of dietary
ﬂavonoids quercetin, rutin, naringenin and naringin. We aimed to pro-
pose their potential metabolites and chemical structures and also to
investigate the abilities of these compounds to interact with cyto-
chrome P450 CYP1A2 and CYP2C9 isoforms. We applied MetaPrint2D,
an improved algorithm for ligand-based site of metabolism prediction,active sites of CYP2C9 (A and C, respectively) and CYP1A2 (B and D, respectively) from
hydroxylation and (D) C3′ aromatic hydroxylation. 3D representation of CYP2C9 and
rbon atoms are shown in gray). The ﬂavonoid compounds are shown as sticks (the car-
on atoms are shown in blue). The blue dotted lines denote hydrogen bonds.
A B
DC
Fig. 4. The two major energetically favored binding clusters of quercetin and rutin in the active sites of CYP2C9 (A and C, respectively) and CYP1A2 (B and D, respectively) from
docking studies. The orientations consistent with (A) and (B) are C5′ aromatic hydroxylation; and the orientations consistent with (C) and (D) are C5′ aromatic hydroxylation
and C8′ dealkylation. 3D representation of CYP2C9 and CYP1A2 is shown in cartoon (green) and some of the amino acid residues are shown with sticks (carbon atoms are
shown in gray). The ﬂavonoid compounds are shown with sticks (carbon atoms in yellow) and the heme group is also shown with sticks (carbon atoms in blue). The blue dotted
lines denote hydrogen bonds.
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lism, combined with structure-based methodologies such as docking
and energy minimization, to predict the binding of the substrates to
the CYP enzymes.
MetaPrint2D is a tool that predicts xenobiotic metabolism through
data-mining and statistical analysis of known metabolic transforma-
tions reported in scientiﬁc literature. The approach adopted was devel-
oped based on the method from Boyer and co-workers (Boyer et al.,
2007) that uses circular ﬁngerprints and substrate/product ratios. The
method was completely developed without pre-existing platforms
and uses fast algorithms. Extensive testing was employed to maximize
the performance of the approach. Comparison with other rule-based
methods based on expert systems indicates that this method is a prom-
ising option for use in combination with other methods (Rydberg,
Vasanthanathan, Oostenbrink, & Olsen, 2009). MetaPrint2D predicted
the formation of C3-hydroxylated and O7′-O-dealkylated products as
major phase I metabolites of the studied ﬂavonoids. It has been shown
that MetaPrint2D correctly predicted the SOMs in about 70–80% of
cases among the three highest-scored atom positions (Adams, 2010).
The advantage of the structure-based metabolism prediction is that
it not only predicts the site of metabolism (metabolic liability), but that
it also elucidates important molecular interactions between substrates
and the active site residues of drug-metabolizing enzymes. These mo-
lecular interactions produce invaluable information for chemical designand redesign when enhancing pharmacokinetic proﬁles and reducing
toxicities (Sun & Scott, 2010).
CYP enzymes mediate reactions that exhibit remarkable regio-
and stereoselectivity. The regioselectivity of CYP450 catalyzed
transformations – the atom or atomswhere the reaction occurs – is de-
termined by a number of factors, including the energy required to re-
move a hydrogen atom from the substrate (hydrogen abstraction
energy), the stability of the resulting carbon radical, and also the struc-
ture and shape of the binding pocket of the speciﬁc CYP450 variant cat-
alyzing the transformation. The amino acid interactions could explain
the substrate orientation within the active site of CYP450.
Mammalian P450 CYP1A1, CYP1A2, CYP2B6, CYP2C9 and CYP3A4
were found to catalyze hydroxylation on the B and C rings of ﬂavonoids,
such as naringenin, in human and mouse liver microsomes (Kagawa,
Takahashi, Ohta, & Harigaya, 2004). The involvement of CYP1A2 as a
major contributor in the metabolism of the ﬂavonones, ﬂavonols and
ﬂavones was veriﬁed by inhibition studies, where potent inhibition
by ﬂuvoxamine, a selective CYP1A2 inhibitor, resulted in reduced for-
mation of the corresponding hydroxylated metabolites (Breinholt,
Rasmussen, Brøsen, & Friedberg, 2003; Breinholt et al., 2002). CYP3A4,
CYP2C9 and CYP2D6 were also capable of catalyzing oxidative metabo-
lism of some of the ﬂavonoids, although to considerably smaller quanti-
ties than CYP1A2. The main metabolic routes of the CYP1A2-catalyzed
oxidation involved 3-hydroxylation and 4′-O-demethylation in the B
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form the structure-based metabolism study of the selected ﬂavonoids.
Water molecules often play an essential role in drug–enzyme
interactions. The displacement of water molecules from the binding
site is one of the main sources of binding free energy (Wang et al.,
2002). Studies of the water molecules in the ligand-binding cavities
of cytochromes P450 indicate that their high mobility facilitates the
movement of the substrates and products into and out of the active
site (de Groot & Ekins, 2002; Rydberg et al., 2009). An ordered water
(wat733)was found in the active site of CYP1A2 and is located at an ap-
propriate distance to form hydrogen bonds with the carbonyl group of
the α-naphthoﬂavone substrate and also with the carbonyl group of
Gly316 in helix I (Sansen et al., 2007). Several water molecules were
identiﬁed to be important for CYP2C9 substrate binding. One of these
water molecules (wat600) is located between the ﬂurbiprofen and the
heme iron at a distance of b3.0 Å allowing for the hydrogen bond
with the backbone carbonyl group of Ala297. Another water molecule
(wat819) is located at the distortion region of helix I, and there is also
a water molecule (wat842) located between ﬂurbiprofen and the turn
region of the substrate recognition site (Wester et al., 2004). Hence,
we included three active-site water molecules in the docking studies
of CYP2C9 (Wat600, Wat819 and Wat842) and one water molecule in
the CYP1A2 active site (Wat733). In CYP2C9, the ﬂavonoid compounds
interact with at least one active-site water molecule (Figs. 3A and C and
4A and C), showing that these water molecules could potentially stabi-
lize the metabolism reactions of the ﬂavonoids quercetin, rutin,
naringenin and naringin. In the CYP1A2 enzyme, the same event was
observed, and the active-site water molecule (Wat733) was involved
in the interactions with the ﬂavonoids (Fig. 3, B and D; Fig. 4, B and D).
Our ﬁnal prediction model is displayed summarizing all the predict-
ed metabolites for naringin and naringenin (Fig. 5), quercetin and rutin
(Fig. 6), using a combination of ligand- and structure-basedmetabolism
prediction tools. Moreover, we have compared the predicted metabo-
lites with the known metabolites of ﬂavonoids using in vivo or in vivo
ﬁndings.Fig. 5. Predicted metabolites for quercetin and rutin using a combination of computationa
presented as order of occurrence. The experimental ﬁndings of the metabolites are in the
al., 2002; Hosny et al., 2001; Nielsen et al., 1998).Fig. 5 shows the highest scoredmetabolites predicted by all compu-
tational methods for quercetin and rutin. In this study, only one phase I
metabolite was found for quercetin (M1) and three metabolites were
expected for rutin. The metabolite predicted for quercetin (M1) was
also observed experimentally using in vitro studies. For rutin, the two
highest scored metabolites predicted by all computational methods
M1 and M2, have been observed experimentally, indicating that our
results are in agreement with in vitro experiments (Breinholt et al.,
2002; da Silva et al., 1998; Hosny, Dhar, & Rosazza, 2001). The M3 me-
tabolite of rutin would be expected to be a minor product.
As we can see from Fig. 6, the highest scored metabolites predicted
by all computational methods were M1 and M2 for naringenin and for
naringin, which are the C3′-hydroxylated and the C3-hydroxylatedme-
tabolites, respectively, were also found experimentally (Breinholt et al.,
2002; Doostdar, Burke, & Mayer, 2001; Heim, Tagliaferro, & Bobilya,
2002; Nielsen, Breinholt, Justesen, Cornett, & Dragsted, 1998). The
naringenin metabolite M3 was only predicted by Metaprint2D. The
C3′ and C3 atoms of the ﬂavonoids are likely to undergo phase I metab-
olism by hydroxylation reactions (Androutsopoulos et al., 2010, 2011).
Breinholt and co-workers have shown that the primary site of ﬂavo-
noid biotransformation was found to be at the 3′- and 4′-position of the
B-ring, resulting in major end-products with 3′,4′-dihydroxylated
B-rings (Breinholt et al., 2002). Similar ﬁndings have been observed in
female rat liver microsomes (Nielsen et al., 1998) suggesting the pres-
ence of a universal route for ﬂavonoid biotransformation across differ-
ent species. As the ﬂavanones naringenin and naringing already have
the hydroxyl group in the 4′-position of B ring, the main metabolites
predicted were the 3′,4′-dihydroxylated. For quercetin and rutin,
which are 3′,4′-dihydroxylated ﬂavones, the products proposed are
trihydroxylated metabolites (M1 for quercetin and rutin). As a result,
our best predictions using the computational methods for ﬂavonoids
corresponded to the known metabolites, using in vitro experiments.
According to our study, signiﬁcant hydrogen-bonding and π–π
stacking interactions with ﬂavonoid molecules and key amino acid res-
idues of CYP1A2 and CYP2C9 enzymes, were means which determinel methods, MetaPrint2D and docking. The metabolites numbers (M1, M2 and M3) are
literature (Breinholt et al., 2002; da Silva et al., 1998; Doostdar et al., 2001; Heim et
Fig. 6. Predicted metabolites for naringenin and naringin using a combination of computational methods, MetaPrint2D and docking. The metabolite numbers (M1, M2, s and M4)
are presented as order of occurrence. The experimental ﬁndings of the metabolites are in the literature (Breinholt et al., 2002; da Silva et al., 1998; Doostdar et al., 2001; Heim et al.,
2002; Hosny et al., 2001; Nielsen et al., 1998).
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tributing to the orientation to the catalytic site are i) the presence of a
sugar chain at the A or C rings ii) the number of hydroxyl groups on
the A and B rings and iii) the polar and steric interactions of sugar
chain on the A or C rings. Similar ﬁndings have been observed in other
molecular modeling (Dai et al., 1998; Iori, da Fonseca, Ramos, &
Menziani, 2005; Lewis, Lake, & Dickins, 2004) and site-directed muta-
genesis studies (Hadjokas et al., 2002; Liu et al., 2004).
Another important ﬁnding is the participation of the amino acid resi-
dues in the metabolism. In CYP2C9, the Asn474, Ser209, Thr304 and
Arg108 residues participated almost in all of the metabolically active
poses, suggesting that these residues are important for the regioselectivity
and positioning of the substrate. The same was observed for the Asp313,
Phe226, Phe256 and Phe260 residues of the CYP1A2 isoform.
The active site of CYP1A2 has been well characterized as being
narrow and lined by residues on helix F and helix I (Ekins, de Groot,
& Jones, 2001; Sansen et al., 2007; Smith, Ackland, & Jones, 1997a,
1997b). The active site is formed mainly by the backbone of residues
Gly316, Ala317, and Asp320. At the top of the site, there is an aromat-
ic cluster formed by Phe226, Phe256, and Phe260. Aromatic sub-
strates are believed to be sandwiched between the planar bottom
and the aromatic top. Thr118, Ser122, and Thr124 are the main candi-
dates to form polar contacts between the protein and the ligands.
Residue Thr223 from helix H is involved in a strong hydrogen bond
with Asp320 of helix I, and both residues are involved in an extensive
network of hydrogen-bonded water molecules and side chains, in-
cluding Tyr189, Val220, Thr498, and Lys500. The X-ray structure
withα-naphthoﬂavone additionally shows a hydrogen bond between
the inhibitor and one of these water molecules (Sansen et al., 2007).Substrates are characterized as neutral or basic, lipophilic, planar
molecules with at least one putative hydrogen bond donating group
(Ekins et al., 2001).
Dai et al. (1998) highlighted in a previous report that although the
active site of CYP1A2 is hydrophobic, signiﬁcant hydrogen-bonding
interactions are promoted between the residues Thr-385 and Arg-108
and the hydroxyl groups of ﬂavonemolecules. As a result, the ﬂavonoid
3,5,7-tri-hydroxyﬂavone was predicted to bind more strongly to the
active site at a perpendicular orientation due to increased hydrogen
bonding, as opposed to ﬂavone and 3,5,7-tri-methoxyﬂavone (Dai
et al., 1998).
The major involvement in ﬂavonoid metabolism of human CYP1A2,
which mediates the formation of metabolites with different biochemi-
cal properties as compared to the parent compound and furthermore
is known to be expressed very differently among individuals, raises
the important question of whether individual differences in the CYP
enzyme activity might affect the beneﬁcial outcome of dietary ﬂavo-
noids, rendering some individuals more or less refractory to the health-
promoting potential of dietary ﬂavonoids.
5. Conclusions
In this work, we described the application of a combined in silico
methodology to explore the prediction of the site of metabolism of di-
etary ﬂavonoid compounds quercetin, rutin, naringenin and naringin.
The results obtained using the computational methods gave valuable
information about the probable metabolites and also about the im-
portant interactions of these compounds have with the amino acid
residues of the active sites of CYP2C9 and CYP1A2. Moreover, the
110 M.C. Sousa et al. / Food Research International 50 (2013) 102–110results presented here afford new opportunities for improving the ap-
plication of dietary ﬂavonoids for the prevention of chronic disorders,
as they're capable to be metabolized by CYP450 family.
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